{"id":"W3155089045","doi":"10.1016/s1470-2045(21)00098-x","title":"Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; AstraZeneca","keywords":"Medicine; BRCA mutation; Internal medicine; Ovarian cancer; Clinical endpoint; Oncology; Olaparib; Placebo; Quality of life (healthcare); Cancer; Response Evaluation Criteria in Solid Tumors; Progression-free survival; Clinical trial; Progressive disease; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003736017,0.0002056936,0.0009839534,0.00007657329,0.00008329705,0.00001202586,0.00004501672,0.00007235478,0.00004374947],"category_scores_gemma":[0.001010661,0.0001134742,0.00004093829,0.0002117111,0.0001556987,0.00007212361,0.00003039249,0.0002473073,4.326208e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003656444,"about_ca_system_score_gemma":0.0006971105,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008623534,"about_ca_topic_score_gemma":0.0003466947,"domain_scores_codex":[0.9976225,0.0009075076,0.0004381231,0.0003690903,0.0002567718,0.0004059841],"domain_scores_gemma":[0.9973162,0.00168124,0.0004429581,0.0002677316,0.00009794164,0.0001939301],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7775418,0.0007727584,0.05399324,0.0002193502,0.00008200283,0.00008030119,0.001962863,0.00006167531,0.0000619748,0.00001931665,0.0002385579,0.1649662],"study_design_scores_gemma":[0.8996809,0.01518811,0.08232863,0.001272913,0.00009073065,0.000005125102,0.0002003997,0.0001629407,0.0002560371,0.00005513187,0.0006255241,0.0001335988],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9890843,0.000989765,0.00002870917,0.005227059,0.0002607075,0.004227206,0.0001127687,0.00002736359,0.00004210321],"genre_scores_gemma":[0.995641,0.0009740201,0.0005126354,0.001730564,0.0000683369,0.0009401643,0.000086098,0.0000239464,0.000023224],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1648326,"threshold_uncertainty_score":0.4627342,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02288432002918147,"score_gpt":0.3707904252599238,"score_spread":0.3479061052307423,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}